A RDS, the more severe form of acute lung injury (ALI), is a common and lethal disease in ICUs worldwide. Clinically, ARDS is characterized by acute respiratory failure with severe hypoxemia and diffuse pulmonary infi ltrates. Despite recent advances in critical care and signifi cant efforts invested in the basic research and clinical trials of ARDS, its mortality rate (35%-45%) has remained relatively unchanged since 1994. 1 ARDS usually develops in patients with predisposing conditions that induce systemic infl ammatory response, such as sepsis, pneumonia, major trauma, multiple transfusions, aspiration, and acute pancreatitis, among which sepsis is the most common cause of ARDS. [2] [3] [4] [5] In a large prospective cohort study, severe sepsis with a suspected pulmonary source (46%) or a nonpulmonary source (33%) was the most common risk factor for ALI. 6 On the other hand, only Background: ARDS may occur after either septic or nonseptic injuries. Sepsis is the major cause of ARDS, but little is known about the differences between sepsis-related and non-sepsis-related ARDS. Methods: A total of 2,786 patients with ARDS-predisposing conditions were enrolled consecutively into a prospective cohort, of which 736 patients developed ARDS. We defi ned sepsis-related ARDS as ARDS developing in patients with sepsis and non-sepsis-related ARDS as ARDS developing after nonseptic injuries, such as trauma, aspiration, and multiple transfusions. Patients with both septic and nonseptic risks were excluded from analysis. Results: Compared with patients with non-sepsis-related ARDS (n 5 62), patients with sepsisrelated ARDS (n 5 524) were more likely to be women and to have diabetes, less likely to have preceding surgery, and had longer pre-ICU hospital stays and higher APACHE III (Acute Physiology and Chronic Health Evaluation III) scores (median, 78 vs 65, P , .0001). There were no differences in lung injury score, blood pH, Pa O 2 /F IO 2 ratio, and Pa CO 2 on ARDS diagnosis. However, patients with sepsis-related ARDS had signifi cantly lower Pa O 2 /F IO 2 ratios than patients with nonsepsis-related ARDS patients on ARDS day 3 ( P 5 .018), day 7 ( P 5 .004), and day 14 ( P 5 .004) (repeated-measures analysis, P 5 .011). Compared with patients with non-sepsis-related ARDS, those with sepsis-related had a higher 60-day mortality (38.2% vs 22.6%; P 5 .016), a lower successful extubation rate (53.6% vs 72.6%; P 5 .005), and fewer ICU-free days ( P 5 .0001) and ventilatorfree days ( P 5 .003). In multivariate analysis, age, APACHE III score, liver cirrhosis, metastatic cancer, admission serum bilirubin and glucose levels, and treatment with activated protein C were independently associated with 60-day ARDS mortality. After adjustment, sepsis-related ARDS was no longer associated with higher 60-day mortality (hazard ratio, 1.26; 95% CI, 0.71-2.22). Conclusion: Sepsis-related ARDS has a higher overall disease severity, poorer recovery from lung injury, lower successful extubation rate, and higher mortality than non-sepsis-related ARDS. Worse clinical outcomes in sepsis-related ARDS appear to be driven by disease severity and comorbidities.
transfusions as defi ned previously, 12 were eligible for inclusion. Exclusion criteria were aged , 18 years, diffuse alveolar hemorrhage, chronic lung diseases other than COPD or asthma, directive to withhold intubation, immunosuppression (other than immunosuppression secondary to corticosteroid therapy), and treatment with granulocyte colony-stimulating factor. Enrolled patients were followed daily for ARDS development on the basis of the American-European Consensus Committee criteria for ARDS. 13 The study was approved by the human subjects committees of Massachusetts General Hospital, Beth Israel Deaconess Medical Center, and the Harvard School of Public Health. Written informed consent was obtained from all participants or their surrogates.
Data Collection and Defi nitions
Patient demographic and baseline clinical characteristics were recorded on study enrollment. Vital signs and laboratory values in the fi rst 24 h of ICU admission were collected, and Acute Physiology and Chronic Health Evaluation (APACHE) III scores were calculated. BMI was calculated based on admission height and weight. Patients were followed for specifi c treatments, including activated protein C (APC) and vasopressors use. Lung injury score was calculated as per Murray et al. 14 To consider the infl uences of pre-ICU hospital stay on sepsis and ARDS, we created a variable indicating whether the pre-ICU hospital stay was Ն 48 h. Patients transferred from other hospitals were considered to have a pre-ICU hospital stay of Ն 48 h.
Sepsis was defi ned as a known or suspected source of systemic infection plus at least two of the following: temperature . 38°C or , 36°C; heart rate . 90 beats/min; respiratory rate . 20 breaths/min or Pa co 2 , 32 mm Hg; or WBC count . 12,000/mm 3 , , 4,000/mm 3 , or . 10% bandemia. Infections were determined based on the treating physician clinical judgment, imaging studies, microbiologic tests collected within 48 h before or after ICU admission, or a combination of these. We defi ned sepsis-related ARDS as that developing in patients with sepsis, and non-sepsis-related ARDS as that developing after nonseptic injuries such as trauma, aspiration, and multiple transfusions. Causes of ARDS were determined by the treating physicians on diagnosis. The classifi cation of ARDS into sepsis-related or non-sepsis related were retrospectively made by two investigators according to causes of ARDS. Patients with both septic and nonseptic risks for ARDS were excluded from analysis. All patients with ARDS were followed until death or 60 days after diagnosis. We used all-cause 60-day mortality as the major clinical outcome. Other short-term outcomes were based on 28 days after ARDS diagnosis, including all-cause 28-day mortality, ICU length of stay (LOS), ICU-free days, total ventilator days, ventilator-free days, and successful extubation.
Statistical Analyses
Categorical variables are presented as frequencies and percentages. All continuous variables were not normally distributed and, thus, are presented as median values and interquartile ranges (IQRs). In univariate analyses, categorical variables were compared by x 2 test or Fisher exact test, and continuous variables were compared by nonparametric Wilcoxon test. Repeated measurements were analyzed by the generalized estimating equation (GEE) model.
Mortality between patients with sepsis-related and non-sepsisrelated ARDS was compared by x 2 test in univariate analysis. Kaplan-Meier estimates and Cox proportional hazards models were used to analyze time to death. In Cox regression models, candidate variables with P , .20 in univariate analyses were entered into the model. We replaced missing values (3.2% of BMI, 18.6% of serum bilirubin, and 19.5% of serum albumin) by the a fraction of patients with sepsis (18%-38%) will develop ARDS. 7 There is signifi cant heterogeneity among patients with ARDS. Many efforts have been made to defi ne pathogenetic or molecular phenotypes that might have signifi cant clinical implications. Currently, ARDS usually is classifi ed into subgroups based on predisposing clinical conditions, such as sepsis related, transfusion related, and trauma associated (or posttraumatic). Although prior studies have found patients with trauma-associated ALI to be less acutely and chronically ill with lower mortality than those with nontraumatic ALI, [8] [9] [10] little is known about the differences between sepsis-related and non-sepsis-related ARDS. Characterization of these two subgroups hopefully will lead to improvements in future research and management of this syndrome. 4 In this study, we hypothesized that sepsis-related ARDS is clinically different from non-sepsis-related ARDS. Therefore, we compared the clinical features and outcomes between these two subtypes in a large prospective cohort. (86.9%), and from the medical ICU (50.8%). Regarding predisposing conditions, 524 (89.4%) patients had sepsis, and 62 (10.6%) had nonseptic injuries. Among patients with sepsis, 373 (71.2%) had septic shock, 109 (20.8%) had bacteremia, and 408 (77.9%) had pneumonia. Seventy-eight patients had both pneumonia and bacteremia. Among patients with nonseptic injuries, 27 (43.6%) had trauma, 35 (56.5%) had multiple transfusions, and 8 (12.9%) had aspiration. Seven patients had both trauma and multiple transfusions, and one patient had both trauma and aspiration. Table 2 shows the demographics and clinical characteristics between ARDS survivors and nonsurvivors. Nonsurvivors were older, had higher APACHE III scores, and had lower BMI than survivors. Sepsis was more common in nonsurvivors, whereas trauma was more common in survivors. Compared with the survivors, nonsurvivors had higher percentages of liver cirrhosis and metastatic cancers and were more likely to have stayed in the hospital for . 48 h before ICU admission. The platelet counts were lower, whereas the serum glucose, bilirubin, and corresponding overall median values. Other covariates had , 1% missing values. We used a backward selection algorithm with criteria of P . .05 for eliminating variables. Considering advances in medical care over time, the analyses were performed with stratifi cation by calendar year. For the fi nal Cox regression models, we used Kolmogorov-type supremum test to check the proportional hazards assumption (all P . .90).
Materials and Methods

Study Design and Patient Inclusion
All data analyses were performed with statistical software SAS, version 9.1 (SAS Institute; Cary, NC). A two-sided P Յ .05 was considered statistically signifi cant. Figure 1 illustrates the enrollment and follow-up of study patients. A total of 2,786 patients with predisposing conditions for ARDS were enrolled into the prospective cohort, of which 736 (26.4%) developed ARDS. We excluded 25 patients with previous enrollment, 17 infected patients who did not fulfi ll sepsis criteria, and 108 patients who had both septic and nonseptic ARDS risk factors, leaving 586 patients for analysis. Table 1 shows the baseline characteristics of study patients. Most patients were men (60.8%), white (90.4%), recruited at Massachusetts General Hospital in Table 3 . Compared to patients with non-sepsisrelated ARDS, those with sepsis-related were more likely to be women ( P 5 .010) and to have diabetes ( P 5 .006), had longer pre-ICU hospital stays ( P , .0001), and were less likely to have preceding surgery ( P , .0001). Patients with sepsis-related ARDS also had signifi cantly higher APACHE III scores ( P , .0001); WBC counts ( P , .0001), hematocrit levels ( P 5 .006), and platelet counts ( P , .0001); and lower serum albumin levels ( P 5 .027) than those with non-sepsisrelated ARDS.
Results
Enrollment, Follow-up, and Baseline Characteristics of Study Patients
A slightly higher percentage of sepsis-related ARDS developed after ICU admission than of non-sepsisrelated ARDS (61.3% vs 50%; P 5 .087). With regard creatinine levels were higher in nonsurvivors than in survivors. There were no signifi cant differences between survivors and nonsurvivors in lung injury scores, blood pH value, Pa o 2 /F io 2 ratio, Pa co 2 , tidal volume, and positive end-expiratory pressure (PEEP). Regarding treatments, more nonsurvivors had vasopressors used within 24 h after ARDS diagnosis.
Clinical Characteristics Between Sepsis-Related and Non-Sepsis-Related ARDS
The characteristics between patients with sepsisrelated ARDS and non-sepsis-related ARDS are shown ARDS than in those with non-sepsis-related ARDS ( P 5 .011).
Clinical Outcomes Between Sepsis-Related and Non-Sepsis-Related ARDS
Patients with sepsis-related ARDS had worse clinical outcomes than those with non-sepsis-related ARDS, with signifi cantly higher 28-day (31.1% vs 16.3%; P 5 .015) and 60-day (38.2% vs 22.6%; P 5 .016) mortality rates, fewer ICU-free days ( P 5 .0001) and ventilator-free days ( P 5 .003), and lower successful extubation rates (53.6% vs 72.6%; P 5 .005) in the fi rst to severity of lung injury on ARDS diagnosis, there were no differences between these two subtypes of ARDS in lung injury score, pH value, Pa o 2 /F io 2 ratio, Pa co 2 , and PEEP level. Although the Pa o 2 /F io 2 ratios were not different on ARDS diagnosis, patients with sepsis-related ARDS had signifi cantly lower Pa o 2 /F io 2 ratios than those with non-sepsis-related ARDS on day 3 ( P = .018), day 7 ( P 5 .004), and day 14 ( P 5 .004) after ARDS diagnosis. In repeated-measures analysis using a GEE model and adjusted for baseline values, the serial Pa o 2 /F io 2 ratios (log-transformed before analysis) on day 3, day 7, and day 14 were signifi cantly lower in patients with sepsis-related 
Discussion
Although sepsis as a cause of ARDS generally is associated with higher mortality than other risk factors, 15, 16 to our knowledge, no study has comprehensively examined the clinical difference between sepsis-related and non-sepsis-related ARDS. Unlike previous studies, we considered ARDS developing in patients with pneumonia who also fulfi lled sepsis criteria as sepsis-related ARDS, grouped all non-sepsisrelated ARDS together, and took into account the reality that a fraction of ARDS may be caused by both septic and nonseptic injuries. Our study demonstrates signifi cant differences between sepsis-related and non-sepsis-related ARDS in clinical features and outcomes. In general, patients with sepsis-related ARDS had a higher disease severity and worse clinical outcomes than those with non-sepsis-related ARDS.
28 days after ARDS diagnosis ( Table 4 ) . Among survivors, patients with sepsis-related ARDS had longer ICU LOS than those with non-sepsis-related ARDS ( P 5 .010). The Kaplan-Meier estimates also showed a signifi cant difference in 60-day survival between patients with sepsis-related and non-sepsis-related ARDS ( P 5 .033 by log-rank test) ( Fig 2 ) .
Multivariate Analysis
In multivariate Cox regression analysis, we identifi ed age (hazard ratio [ ( Table 5 ) . Sepsis-related ARDS was not independently associated with increased ARDS mortality compared with non-sepsis-related ARDS (HR, 1.26; 95% CI, 0.71-2.22).
Patients With ARDS Excluded From Comparisons
There were 17 infected patients who did not meet sepsis criteria, including 15 with pneumonia, one with bacteremia, and one with both pneumonia and bacteremia. The median APACHE III score (69; IQR, 62-80) and 28-day (23.5%) and 60-day (29.4%) mortality rates of these patients were between the data in patients with sepsis-related and non-sepsisrelated ARDS. Another 108 patients with both sepsic and nonseptic ARDS risk factors also were excluded from comparisons. Their median APACHE III score (72; IQR, 55-89) and 28-day (31.5%) and 60-day (38.9%) mortality rates were close to the data in the patients with sepsis-related ARDS. Table 2 were entered into the model. The variable representing sepsis-related vs non-sepsis-related ARDS was forced to be retained in the fi nal model, whereas the covariates were selected using backward selection algorithm with criteria of P . .05 for eliminating variables.
with the premise that defi cient neutrophil function may predispose these patients to severe infections but, conversely, may protect the lung from profound infl ammation during severe infections. We identifi ed seven independent predictors of ARDS mortality. From prior studies, age, APACHE III score, liver cirrhosis, and metastatic cancers are known predictors of ARDS mortality. 5, 20, [30] [31] [32] In a recent study, we found that higher admission serum bilirubin levels were associated with subsequent ARDS development and mortality. 33 The independent associations of admission serum glucose level and APC therapy with ARDS mortality have not been previously reported.
Stress hyperglycemia is common in acute critical illnesses. Although admission hyperglycemia has been associated with increased mortality in critically ill patients, this association is not uniformly observed in all ICU populations, 34, 35 with more evidence in surgical ICU patients but less in medical ICU patients. 34, [36] [37] [38] Many studies demonstrating admission blood glucose level as an independent outcome predictor were carried out in patients with acute vascular problems like stroke, myocardial infarction, and coronary artery bypass grafting. [39] [40] [41] [42] Interestingly, ARDS, with diffuse pulmonary microvascular damage as the pathologic hallmark, is also a syndrome of acute vascular illness. A randomized controlled trial of early blood glucose control in at-risk subjects is ongoing and will further clarify to role of hyperglycemia (or insulin therapy) on ARDS (trial registration: clinicaltrials.gov; Identifi er: NCT00605696).
Recombinant human APC has both anticoagulant and antiinfl ammatory properties and is US Food and Drug Administration-approved for the treatment of high disease severity severe sepsis. Given that infl ammation and coagulation both play important roles in the pathogenesis of ARDS 43, 44 and that lower levels of plasma protein C were independent predictors of ARDS mortality, 45 APC may also be effective in treating ARDS. A recent phase II clinical trial showed that APC did not improve outcome in lower disease severity ALI but did improve dead space fraction. 46 Our study included patients with ARDS with greater severity of illness, of which 89% had sepsis. We found that treatment with APC was independently associated with decreased mortality. However, the survival benefi t of APC in patients with ARDS might come from the effective treatment of severe sepsis or septic shock, not from effective treatment of ARDS per se. Of note, the effectiveness of APC for septic shock recently has been called into question, and an international trial of APC in septic shock is under way. 47 Hopefully, this trial will lead to a better understanding of the role of APC, if any, in sepsis-related ARDS.
ARDS is a heterogeneous syndrome associated with complex interactions among the predisposing conditions, comorbidities, and genetic determinants. This heterogeneity leads to complexity and uncertainty in the study of this syndrome. 4 It is possible that clinical trials have not found a treatment effect that truly exists because a therapy that benefi ts one subgroup may not benefi t another subgroup. 17 The genetic susceptibility to ARDS also shows differences among subgroups. 18 A better classifi cation of ARDS subgroups, therefore, is crucial in the future research and management of ARDS. In 1998, Gattinoni and colleagues 19 fi rst described the differences of underlying pathology, respiratory mechanics, and response to mechanical ventilation between pulmonary and extrapulmonary ARDS. However, later studies showed that there are no differences in mortality or ICU LOS between these two groups. 16, [20] [21] [22] In the present study, we found signifi cant differences in characteristics and outcomes between sepsis-related and non-sepsisrelated ARDS. Our fi ndings warrant further studies to understand whether these two ARDS subtypes may represent different syndromes.
How sepsis-related ARDS differs pathophysiologically from non-sepsis-related ARDS remains largely unknown. Studies measuring circulating biomarkers in patients with ARDS showed that protein C level was lower in patients with sepsis-related ARDS than in those with non-sepsis-related ARDS, whereas procalcitonin, neopterin, von Willebrand factor antigen, soluble intercellular adhesion molecule-1, and soluble E-selectin levels were higher. [23] [24] [25] Plasma cytokines also vary among clinical risk factors because interleukin-6, -8, and -10 levels are known to be higher in patients with ARDS caused by sepsis and pneumonia. 26 These factors together suggest a higher degree of acute infl ammation, endothelial cell activity, and coagulation activation in sepsis-related ARDS than in non-sepsis-related ARDS. Hemodynamics, ventricular function, and oxygen delivery and consumption, however, are not different between sepsisrelated and non-sepsis-related ARDS. 23 Our study revealed no signifi cant difference between sepsisrelated and non-sepsis-related ARDS in baseline Pa o 2 /F io 2 ratio and severity of lung injury. However, patients with sepsis-related ARDS had lower serial Pao 2 /F io 2 ratios after ARDS diagnosis, indicating a poorer recovery from lung injury than patients with non-sepsis-related ARDS.
We found diabetes to be more common in sepsisrelated ARDS than in non-sepsis-related ARDS. Diabetes is associated with lower risk of developing ARDS, but how it may protect against ARDS remains unclear. 27, 28 Studies have shown defects of neutrophil chemotactic, phagocytic, and microbicidal function in patients with diabetes. 29 Our fi nding is consistent recruitment; Andrea Shafer and Starr Sumpter for research support; Janna Frelich, Marcia Chertok, and Julie DelPrato for data management; and the patients and staff of the ICUs at Massachusetts General Hospital and Beth Israel Deaconess Medical Center.
A major strength of this study is that it was conducted within a large, well-defi ned, two-center, multiple-ICU cohort of ARDS. All data were collected prospectively, thus avoiding recall biases. In addition, excluding from analyses patients with both septic-related and non-septic-related ARDS reduced pos sible bias from misclassifi cation. Nevertheless, we acknowledge several limitations to our study. First, the number of patients with non-sepsis-related ARDS was relatively small largely due to the exclusion of 108 patients with both sepsis-related and nonsepsis-related ARDS. Second, we did not collect data for antibiotic appropriateness, time delay to the diagnosis of sepsis, and time to meeting resuscitation goals, all of which might affect the outcomes in critically ill patients. [48] [49] [50] Finally, patients with immunosuppression (other than secondary to steroids) were excluded in our study, thus generalization to populations including such patients should be made with caution.
In summary, sepsis-related ARDS is associated with a higher overall disease severity, poorer recovery from lung injury, lower successful extubation rate, longer ICU stay, and higher mortality than non-sepsis-related ARDS. Worse clinical outcomes in sepsis-related ARDS appear to be driven by disease severity and comorbidities. Our fi ndings warrant further studies on potential pathophysiologic differences to understand whether sepsis-related and non-sepsis-related ARDS may represent different disease entities.
Acknowledgments
Author contributions: Dr Sheu: contributed to the planning of the study, study design, data analyses and interpretation, and manuscript preparation and review. Dr Gong: contributed to the planning of the study, study design, assembly of the study patients, and manuscript preparation and review. Dr Zhai: contributed to the planning of the study, study design, and manuscript preparation and review. Dr Chen: contributed to the planning of the study, data analysis and interpretation, and manuscript preparation and review. Dr Bajwa: contributed to the planning of the study, assembly of study patients, and manuscript preparation and review. Dr Clardy: contributed to the planning of the study, assembly of study patients, and manuscript preparation and review. Dr Gallagher: contributed to the planning of the study, assembly of the study patients, and manuscript preparation and review. Dr Thompson: contributed to the planning of the study, assembly of the study patients, and manuscript preparation and review. Dr Christiani: contributed to the planning of the study, study design, and manuscript preparation and review. Financial/nonfi nancial disclosures: The authors have reported to CHEST the following confl icts of interest: Dr Thompson reports fi nancial support from Eli Lilly for his role as the co-principal investigator of the PROWESS-SHOCK study, a randomized trial of activated protein C vs placebo for septic shock. Drs Sheu, Gong, Zhai, Chen, Bajwa, Clardy, Gallagher, and Christiani have reported to CHEST that no potential confl icts of interest exist with any companies/organizations whose products or services may be discussed in this article. Other contributions: We thank Thomas McCabe, Julia Shin, Hanae Fujii-Rios, Ian Taggart, and Kezia Ellison for patient
